Supplemental Figure 1

DCS Iraq-Consort Table

Enrollment

Assessed for eligibility (n=343)

- Excluded at Pre-Treatment Assessment (n=5)
 - -Withdrew Consent at Pre (n=1)
 - -Screen Failed at Pre (n=4)

Excluded After Phone Screen (n=182)

- Not meeting inclusion criteria (n=98)
- Declined to participate (n=17)
- Other reasons (n=67)

Randomized (n=156) D-cycloserine (n=53) Alprazolam (n=50) Placebo (n=53)

Allocation

Post/Completed Treatment (n=97)

- -Lost to Study after Pre (n=31)
- -Lost to Study after T1 (n=4)
- -Lost to Study after T2 (n=6)
- -Lost to Study after T3 (n=8)
- -Lost to Study after T4 (n=6)
- -Lost to Study after T5 (n=2)
- -Lost to Study after T6 (n=1)
- -Completed 3 Mo F/U, but not Post-Treatment Assessment (n=1)

Follow-Up

D-cycloserine Follow-ups

Completed Posttreatment (n=28)

Completed 3-Month (n=21)

Completed 6-Month (n=18)

Completed 12-Month (n=18)

Alprazolam Follow-ups

Completed Posttreatment (n=35)

Completed 3-Month (n=29)

Completed 6-Month (n=25)

Completed 12-Month (n=22)

Placebo Follow-ups

Completed Posttreatment (n=34)

Completed 3-Month (n=24)

Completed 6-Month (n=23)

Completed 12-Month (n=20)